Explore more about: COVID-19

Researchers funded by NIH's RADx Tech program have developed a fast, cost-effective method to detect the circulation of SARS-CoV-2 variants. The team adopted a customizable genotyping approach to identify known variants and subvariants—an approach that can augment current surveillance.

A new type of COVID-19 test is hitting the market, and could change how we detect the virus. MicroGEM, a Virginia-based molecular biology company with a Charlottesville office, is using its new saliva test to track COVID-19. Source: NBC TV12 Richmond, Virginia.

Two recent studies supported by the National Institutes of Health Rapid Acceleration of Diagnostics (RADx) Tech program demonstrate how widespread distribution of COVID-19 at-home antigen tests can be used as an effective public health strategy to reduce the spread of the disease. Source: UMass Chan

A new rapid PCR COVID-19 test invented by Northwestern University faculty and Minute Molecular Diagnostics has received FDA emergency use authorization.

A small preliminary study from Northwestern Medicine has shown that a blood test may identify risk of stillbirth and placentitis in pregnant individuals who have had COVID-19. The finding builds on another study with similar results and could have implications in how physicians screen for and address high-risk pregnancies.

RADx Tech program has issued contracts to help meet the ongoing needs and challenges of COVID-19 diagnostic testing.

The National Institutes of Health’s Rapid Acceleration of Diagnostics (RADx®) Tech program is working to identify necessary elements of at-home COVID-19 diagnostic test kits that may be used independently by people with disabilities.

Siemens Healthineers AG will supply 50 million rapid Covid-19 test kits as part of President Joe Biden‘s push to deliver 1 billion free at-home tests to Americans, the Defense Department said.

Fluidigm, "the South San Francisco-based company, which landed NIH money in a Shark Tank-style program for Covid-19 testing, announced that it will take on an investment worth $250 million from Casdin Capital and Viking Global investors, ". The company "will also rebrand, and call itself Standard BioTools.

Mammoth Biosciences has secured an emergency authorization from the FDA for its high-throughput COVID-19 test, which is powered by CRISPR gene-editing enzymes.